Literature DB >> 2975535

Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.

S Yamaguchi1, M Onji, H Kondoh, H Miyaoka, Y Ohta.   

Abstract

Nine patients with chronic hepatitis type B were treated with recombinant interleukin 2 (rIL-2). Side effects were limited to low-grade fever and headache, which were transient and tolerable for the patients. Seven normal volunteers and nine patients with chronic active hepatitis were administered by one bolus of 500 units of rIL-2. Acute effects of rIL-2 administration on lymphoid cells included a rapid decrease in lymphocytes, especially in cytotoxic T cells and natural killer cells. These acute effects resolved within 24 hours. There was no difference in the changes of immunological parameters between normal volunteers and patients. The same effects were seen during 28 days of rIL-2 administration. The number of lymphocytes and CD4 positive cells was increased after rIL-2 administration for 28 days (P less than 0.01). Natural killer cell activity, especially that of CD16+ and Leu-7- cells was also increased (P less than 0.05). These effects may favour the elimination of virus-infected hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2975535      PMCID: PMC1541693     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.

Authors:  J R Ortaldo; A T Mason; J P Gerard; L E Henderson; W Farrar; R F Hopkins; R B Herberman; H Rabin
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

2.  Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2.

Authors:  P Ralph; G Jeong; K Welte; R Mertelsmann; H Rabin; L E Henderson; L M Souza; T C Boone; R J Robb
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

3.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

4.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

5.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

6.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens.

Authors:  L L Lanier; A M Le; J H Phillips; N L Warner; G F Babcock
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

7.  Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis.

Authors:  M Onji; H Kondoh; N Horiike; S Yamaguchi; Y Ogawa; I Kumon; Y Ohta
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

8.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Authors:  M T Lotze; Y L Matory; S E Ettinghausen; A A Rayner; S O Sharrow; C A Seipp; M C Custer; S A Rosenberg
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

9.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

10.  A sensitive micromethod for generating and assaying allogeneically induced cytotoxic human lymphocytes.

Authors:  J M Zarling; M McKeough; F H Bach
Journal:  Transplantation       Date:  1976-06       Impact factor: 4.939

View more
  2 in total

1.  Treatment of mice with human recombinant interleukin-2 augments resistance to the facultative intracellular pathogen Listeria monocytogenes.

Authors:  M Haak-Frendscho; K M Young; C J Czuprynski
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.